Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The investigators conduct this study to investigate whether oral administration of Dimethyl
Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and
effective in alleviating PHE and neurologic deficits in patients with ICH.